mRNA Encoding a Bispecific Single Domain Antibody Construct Protects against Influenza A Virus Infection in Mice

To date, mRNA-based biologics have mainly been developed for prophylactic and therapeutic vaccination to combat infectious diseases or cancer. In the past years, optimization of the characteristics of in vitro transcribed mRNA has led to significant reduction of the inflammatory responses. Thanks to...

Full description

Saved in:
Bibliographic Details
Main Authors: Lien Van Hoecke (Author), Rein Verbeke (Author), Dorien De Vlieger (Author), Heleen Dewitte (Author), Kenny Roose (Author), Sharon Van Nevel (Author), Olga Krysko (Author), Claus Bachert (Author), Bert Schepens (Author), Ine Lentacker (Author), Xavier Saelens (Author)
Format: Book
Published: Elsevier, 2020-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_decaab1f652f4c3390dafc7e91faf84c
042 |a dc 
100 1 0 |a Lien Van Hoecke  |e author 
700 1 0 |a Rein Verbeke  |e author 
700 1 0 |a Dorien De Vlieger  |e author 
700 1 0 |a Heleen Dewitte  |e author 
700 1 0 |a Kenny Roose  |e author 
700 1 0 |a Sharon Van Nevel  |e author 
700 1 0 |a Olga Krysko  |e author 
700 1 0 |a Claus Bachert  |e author 
700 1 0 |a Bert Schepens  |e author 
700 1 0 |a Ine Lentacker  |e author 
700 1 0 |a Xavier Saelens  |e author 
245 0 0 |a mRNA Encoding a Bispecific Single Domain Antibody Construct Protects against Influenza A Virus Infection in Mice 
260 |b Elsevier,   |c 2020-06-01T00:00:00Z. 
500 |a 2162-2531 
500 |a 10.1016/j.omtn.2020.04.015 
520 |a To date, mRNA-based biologics have mainly been developed for prophylactic and therapeutic vaccination to combat infectious diseases or cancer. In the past years, optimization of the characteristics of in vitro transcribed mRNA has led to significant reduction of the inflammatory responses. Thanks to this, mRNA therapeutics have entered the field of passive immunization. Here, we established an mRNA treatment that is based on mRNA that codes for a bispecific single-domain antibody construct that can selectively recruit innate immune cells to cells infected with influenza A virus. The constructs consist of a single-domain antibody that binds to the ectodomain of the conserved influenza A matrix protein 2, while the other single-domain antibody binds to the activating mouse Fcγ receptor IV. Formulating the mRNA into DOTAP (1,2-dioleoyl-3-trimethylammonium-propane)/cholesterol nanoparticles and delivering these intratracheally to mice allowed the production of the bispecific single-domain antibody in the lungs, and administration of these mRNA-particles prior to influenza A virus infection was associated with a significant reduction in viral titers and a reduced morbidity in mice. Overall, our data provide evidence that the local delivery of mRNA encoding a bispecific single-domain antibody format in the lungs could be a promising pulmonary antiviral prophylactic treatment. 
546 |a EN 
690 |a mRNA 
690 |a mRNA therapeutics 
690 |a Influeanza A 
690 |a passive immunization 
690 |a matrix protein 2 
690 |a nanoparticles 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Molecular Therapy: Nucleic Acids, Vol 20, Iss , Pp 777-787 (2020) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S2162253120301232 
787 0 |n https://doaj.org/toc/2162-2531 
856 4 1 |u https://doaj.org/article/decaab1f652f4c3390dafc7e91faf84c  |z Connect to this object online.